Glofitamab & TALAPRO - 2
from OncoPharm Hosted by John Bossaer
This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide. TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 12 minutes long.
When was this OncoPharm episode published?
This episode was published on June 22, 2023.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.